A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial
The ExTINGUISH trial will determine the safety and efficacy of inebilizumab as a treatment of NMDAR encephalitis while evaluating the utility of clinical, cognitive, and quality-of-life outcome measures and supporting standardized collection and measurement of biofluid biomarkers. These innovations will inform development of future treatments and trials for patients with NMDAR encephalitis and other types of autoimmune encephalitis. The ExTINGUISH trial opened to enrollment of adult patients (older than 18 years) in 2022 and pediatric patients (older than 12 years) in 2024; enrollment is ongoing.
Authors
- Susan Flavin (ORCID: https://orcid.org/0000-0002-5587-4552)
- Hyun Joo Cho (ORCID: https://orcid.org/0000-0002-5926-7864)
- Ursula Utz
- Eliezer Katz (ORCID: https://orcid.org/0000-0003-4892-4918)
- Erin Steinhart
- Eric C. Klawiter (ORCID: https://orcid.org/0000-0002-3429-2633)
- Elizabeth Klingner
- Merit Cudkowicz (ORCID: https://orcid.org/0000-0002-7075-1681)
- James C. Torner (ORCID: https://orcid.org/0000-0003-0979-4874)
- David Klements (ORCID: https://orcid.org/0000-0002-3391-6010)
- Maarten J. Titulaer (ORCID: https://orcid.org/0000-0002-1033-3840)
- Josep Dalmau (ORCID: https://orcid.org/0000-0001-5856-2813)
- Gregory Scott Day (ORCID: https://orcid.org/0000-0001-5133-5538)
- Dixie Ecklund (ORCID: https://orcid.org/0000-0001-6086-962X)
- Stacey Lynn Clardy (ORCID: https://orcid.org/0000-0001-6600-9428)
- J. Robinson Singleton (ORCID: https://orcid.org/0000-0002-6456-0045)
- Ka‐Ho Wong (ORCID: https://orcid.org/0000-0001-9597-8105)
- Janel Fedler (ORCID: https://orcid.org/0000-0002-2361-6604)
- John N. Ratchford (ORCID: https://orcid.org/0000-0003-1987-0076)
- David B. Clifford (ORCID: https://orcid.org/0000-0001-5719-1555)
- Christina Desir
- Christopher S. Coffey (ORCID: https://orcid.org/0000-0002-8130-5484)
- Annalisa Dialino-Felix
- Bruce Pearson
- Cornelia Kamp (ORCID: https://orcid.org/0000-0003-4158-8691)
- L.V. Dill
- Michele Costigan
Institutions
- National Institutes of Health (US)
- Amgen (United States) (US)
- Washington University in St. Louis (US)
- University of Utah (US)
- Erasmus MC (NL)
- Massachusetts General Hospital (US)
- Clinical Research Institute (US)
- VA Salt Lake City Healthcare System (US)
- National Institute of Neurological Disorders and Stroke (US)
- Hospital Clínic de Barcelona (ES)
- Mayo Clinic in Florida (US)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- University of Rochester (US)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Neurology Open Access
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1212/wn9.0000000000000007
- Citations
- 6
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.34